Picture loading failed.

Pre-Made Golimumab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Golimumab is a human monoclonal antibody which is used as an immunosuppressive medication and sold under the brand name Simponi. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism.

Order information

Delivery impact due to the Coronavirus Outbreak

With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.

Catalog No. Package Price(In USD) Qty (Quantity) Sum(In USD)
GMP-Bios-ab-249-1mg 1mg 3090
GMP-Bios-ab-249-10mg 10mg 21890
GMP-Bios-ab-249-100mg 100mg 148000
GMP-Bios-ab-249-xmg ≥100mg Inquiry
Shipping Cost: 760.00


Products Name (INN Index) Pre-Made Golimumab biosimilar, Whole mAb, Anti-TNFA/TNF Antibody: Anti-DIF/TNFSF2/TNLG1F therapeutic antibody
INN Name Golimumab
FormatWhole mAb
Species ReactivityHuman
CH1 IsotypeIgG1
VD LCKappa
Highest_Clin_Trial (Jan '20)Approved
Est. StatusActive
100% SI Structure5yoy:RO:IF:QN:GD:HE:PM
99% SI StructureNone
95-98% SI StructureNone
Year Proposed2004
Year Recommended2005
CompaniesCentocor;Centocor Ortho Biotech;Janssen Biotech;Merck & Co;Mitsubishi Tanabe Pharma Corporation;Medarex
Conditions ApprovedAnkylosing spondylitis;Juvenile rheumatoid arthritis;Non-radiographic axial spondyloarthritis;Psoriatic arthritis;Rheumatoid arthritis;Ulcerative colitis
Conditions ActiveHearing disorders;Type 1 diabetes mellitus
Conditions DiscontinuedAsthma;Cardiovascular disorders;Sarcoidosis;Uveitis
Development TechMedarex UltiMAb Mouse